Almaject, Inc. drugs

8 results
  • dexrazoxane

    (Dexrazoxane for Injection)
    Almaject, Inc.
    Dexrazoxane for Injection is indicated to reduce cardiomyopathy incidence and severity in women with metastatic breast cancer receiving doxorubicin, after a cumulative dose of 300 mg/m², who will continue doxorubicin therapy for tumor control. It should not be used at the start of doxorubicin treatment.
  • dexrazoxane

    (Dexrazoxane for Injection)
    Almaject, Inc.
    Dexrazoxane for Injection is indicated to reduce the incidence and severity of cardiomyopathy in women with metastatic breast cancer receiving cumulative doxorubicin doses of 300 mg/m² or more, who will continue doxorubicin therapy for tumor control. It should not be used at the start of doxorubicin therapy.
  • regadenoson

    (Regadenoson)
    Almaject, Inc.
    Regadenoson injection is indicated as a pharmacologic stress agent for radionuclide myocardial perfusion imaging (MPI) in patients who are unable to perform adequate exercise stress testing.
  • temsirolimus

    (Temsirolimus Injection)
    Almaject, Inc.
    Temsirolimus injection is indicated for the treatment of advanced renal cell carcinoma.